The coronary stent market in the Asia-Pacific (APAC) region is witnessing sustained growth, driven by rising coronary artery disease (CAD) prevalence, an aging population, and increased access to healthcare. Against this backdrop, the market is poised to grow at a compound annual growth rate (CAGR) of 3.2% in APAC between 2024 and 2034, outpacing the global CAGR of 1.2% over the same period, forecasts GlobalData, a leading data and analytics company.
China plays a central role in this regional trend. In recent years, the country has seen a substantial rise in percutaneous coronary intervention (PCI) procedures. Contributing factors include expanded medical insurance coverage, a growing focus on cardiovascular health, and significant price reductions for coronary stents through centralized procurement policies. As a result, the Chinese PCI market is expected to become increasingly saturated and fragmented, with participation from large, medium, and small-scale companies.
Coronary stenting has become a standard clinical approach for managing CAD and acute coronary syndrome (ACS). Drug eluting stents (DES) dominate both the global and APAC markets, due to improved clinical outcomes and widespread physician adoption. Bare metal stents (BMS), once widely used, now account for a shrinking share of the market. Bioabsorbable stents (BAS), while still in early stages of adoption, are forecasted to see the highest growth in APAC, with a projected CAGR exceeding 6% through 2034.
Thomas Fleming, Medical Analyst at GlobalData, comments: “Despite the clinical promise of BAS, challenges remain. The current devices face limitations in strength, cost, and long-term outcomes. Technical drawbacks of earlier-generation devices, such as thicker struts, has contributed to slow adoption. The ongoing research and development aim to address these issues, though commercial viability will depend on future clinical data and regulatory support.”
Market drivers include increasing CAD incidence linked to lifestyle changes, urbanization, and rising rates of obesity, diabetes, and hypertension. At the same time, barriers such as high treatment costs, post-procedural complications, and limited reimbursement frameworks continue to shape the market landscape.
Fleming concludes: “Overall, the APAC region presents a growing opportunity for coronary stent manufacturers, especially in the DES and emerging BAS segments, as healthcare systems evolve and demand for minimally invasive cardiovascular treatments expands.”
